Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Operating Officer | February 15, 2018 | February 23, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,612 |
Ending reported balance
After 2018-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 16,152 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 9,460 · Balance 25,612 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
Quince Therapeutics, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2030-06-07 | Direct | 11,029 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 11,029 · Balance 11,029 F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2020 Filed Jun 9, 2020 20:22 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 11,029 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001209191-20-035425 · doc4.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2030-06-07 F1 · derivative.exercise_date: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. Read SEC document |
| May 13, 2019 Filed Mar 12, 2020 16:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 30,000 | $17.00 | $510,000.00 |
DisclosureSEC source: 0001209191-20-018558 · doc4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 9,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008135 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,612 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Read SEC document |
| February 15, 2018 Filed Feb 23, 2018 23:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 340 | $62.35 | $21,198.15 |
DisclosureSEC source: 0001127602-18-008135 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,152 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 10, 2018 Filed Feb 13, 2018 21:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005553 · form4.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,184 Underlying: Common Stock · 908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 10, 2018 Filed Feb 13, 2018 21:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 425 | $79.32 | $33,711.00 |
DisclosureSEC source: 0001127602-18-005553 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,812 Read SEC document |
| February 10, 2018 Filed Feb 13, 2018 21:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005553 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 3, 2018 02:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003872 · form4.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,092 Underlying: Common Stock · 620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 01, 2018 Filed Feb 3, 2018 02:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 218 | $83.49 | $18,200.82 |
DisclosureSEC source: 0001127602-18-003872 · form4.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,329 Read SEC document |
| February 01, 2018 Filed Feb 3, 2018 02:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003872 · form4.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 02:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,259 | $83.80 | $189,304.20 |
DisclosureSEC source: 0001127602-18-003872 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,927 Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 02:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003872 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,186 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on January 31, 2018. Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 01:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,422 | $73.02 | $249,874.44 |
DisclosureSEC source: 0001127602-17-031968 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,076 Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 01:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 6,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031968 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,498 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on November 9, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025602 · form4.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 Underlying: Common Stock · 910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F1 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 453 | $72.70 | $32,933.10 |
DisclosureSEC source: 0001127602-17-025602 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,688 Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025602 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,460 | $66.92 | $231,543.20 |
DisclosureSEC source: 0001127602-17-017962 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 Read SEC document |
| May 10, 2017 Filed May 12, 2017 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 6,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-017962 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,691 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on May 10, 2017. Read SEC document |
| February 15, 2017 Filed Feb 22, 2017 02:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 315 | $59.33 | $18,688.95 |
DisclosureSEC source: 0001127602-17-007543 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005843 · form4.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,622 Underlying: Common Stock · 908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 317 | $66.36 | $21,036.12 |
DisclosureSEC source: 0001127602-17-005843 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,566 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005843 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 115,870 | $72.25 Strike: $72.25 | $8,371,607.50 |
DisclosureSEC source: 0001127602-17-004207 · form4.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,870 Underlying: Common Stock · 115,870 shares Expires 2027-02-02 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-003938 · form4.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,530 Underlying: Common Stock · 620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 215 | $72.82 | $15,656.30 |
DisclosureSEC source: 0001127602-17-003938 · form4.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-003938 · form4.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2016 Filed Jan 9, 2017 19:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001338 · form5.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,150 Underlying: Common Stock · 910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2016 Filed Jan 9, 2017 19:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 466 | $78.90 | $36,767.40 |
DisclosureSEC source: 0001127602-17-001338 · form5.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570 Read SEC document |
| August 10, 2016 Filed Jan 9, 2017 19:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-001338 · form5.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2016 Filed Jun 14, 2016 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 83,880 | $0.00 Strike: $84.45 | $0.00 |
DisclosureSEC source: 0001127602-16-055536 · form4.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,880 Underlying: Common Stock · 83,880 shares Expires 2026-06-10 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Disposition to issuerPerformance Shares · Derivative | 11,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001952 · edgar.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,931 Underlying: Common Stock · 11,130 shares Expires not disclosed F4 · shares: Represents shares of the Issuer's common stock that were subject to a performance share award made to the Reporting Person on November 6, 2013. That award was subject to both performance-vesting and service-vesting requirements based on his status as Executive Vice President in charge of Commercial Operations. Prior to the satisfaction of the applicable vesting requirements, the award was cancelled on the date reported in Column 3 in connection with his change to part-time employment as a senior advisor. F4 · derivative.exercise_date: Represents shares of the Issuer's common stock that were subject to a performance share award made to the Reporting Person on November 6, 2013. That award was subject to both performance-vesting and service-vesting requirements based on his status as Executive Vice President in charge of Commercial Operations. Prior to the satisfaction of the applicable vesting requirements, the award was cancelled on the date reported in Column 3 in connection with his change to part-time employment as a senior advisor. F4 · derivative.expiration_date: Represents shares of the Issuer's common stock that were subject to a performance share award made to the Reporting Person on November 6, 2013. That award was subject to both performance-vesting and service-vesting requirements based on his status as Executive Vice President in charge of Commercial Operations. Prior to the satisfaction of the applicable vesting requirements, the award was cancelled on the date reported in Column 3 in connection with his change to part-time employment as a senior advisor. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001952 · edgar.xml · derivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,480 Underlying: Common Stock · 2,480 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001179110-14-001952 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 11,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001418 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,418 F2 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on February 1, 2013. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2015. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 21,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001418 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,506 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| January 23, 2014 Filed Jan 28, 2014 01:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 100,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001179110-14-001424 · edgar.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,508 Underlying: Common Stock · 100,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2014 Filed Jan 28, 2014 01:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $81.44 | $8,144,150.00 |
DisclosureSEC source: 0001179110-14-001424 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,418 F3 · price: Sale prices reported for the transactions reported here range from $80.97 to $81.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 23, 2014 Filed Jan 28, 2014 01:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $16.40 | $1,639,500.00 |
DisclosureSEC source: 0001179110-14-001424 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2013 Filed Dec 24, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 75,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001179110-13-018500 · edgar.xml · derivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,508 Underlying: Common Stock · 75,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 20, 2013 Filed Dec 24, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 75,000 | $74.19 | $5,564,452.50 |
DisclosureSEC source: 0001179110-13-018500 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,840 F3 · price: Sale prices reported for the transactions reported here range from $73.75 to $74.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 20, 2013 Filed Dec 24, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 75,000 | $16.40 | $1,229,625.00 |
DisclosureSEC source: 0001179110-13-018500 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2013 Filed Nov 25, 2013 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 75,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001179110-13-017003 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,508 Underlying: Common Stock · 75,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 22, 2013 Filed Nov 25, 2013 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 38,000 | $74.77 | $2,841,104.20 |
DisclosureSEC source: 0001179110-13-017003 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,840 F4 · price: Sale prices reported for the transactions reported here range from $74.37 to $74.90. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document |
| November 22, 2013 Filed Nov 25, 2013 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 37,000 | $73.90 | $2,734,444.30 |
DisclosureSEC source: 0001179110-13-017003 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,840 F3 · price: Sale prices reported for the transactions reported here range from $73.35 to $74.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 22, 2013 Filed Nov 25, 2013 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 75,000 | $16.40 | $1,229,625.00 |
DisclosureSEC source: 0001179110-13-017003 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2013 Filed Oct 25, 2013 21:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 75,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001179110-13-015757 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,508 Underlying: Common Stock · 75,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 23, 2013 Filed Oct 25, 2013 21:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $69.20 | $172,988.00 |
DisclosureSEC source: 0001179110-13-015757 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,840 F4 · price: Sale prices reported for the transactions reported here range from $69.14 to $69.30. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document |
| October 23, 2013 Filed Oct 25, 2013 21:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 72,500 | $68.54 | $4,969,012.25 |
DisclosureSEC source: 0001179110-13-015757 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,340 F3 · price: Sale prices reported for the transactions reported here range from $68.13 to $69.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 23, 2013 Filed Oct 25, 2013 21:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 75,000 | $16.40 | $1,229,625.00 |
DisclosureSEC source: 0001179110-13-015757 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.